OBJECTIVES: The objective of this study is to assess the characteristics of relapsing remitting multiple sclerosis patients taking disease modifying therapies (DMTs) in the US.  METHODS: A large US administrative retrospective claims database was used to identify patients diagnosed with Multiple Sclerosis (MS) and were prescribed DMTs between January 2010 to December 2012 were included in the study. All patients were ≥ 18 years of age and continuously enrolled in the same health plan for a year. Descriptive statistics and chi-square tests were performed on the data and statistical significance level was set a priori at 0.05. RESULTS: There were a total of 741,065 patients that met the study inclusion criteria. The mean age of the patients was 52.38 ± 10.50 years, 75.7% of the patients were females, and majority of the patients were between 41 to 64 years of age (73.5%). Thirty two percent of the patients were from East, 34.6% were from Midwest, 25% from South and 7.8% is from West region. 56.6% of the patients were on a group coverage plan and 62.6% of the patients were on a DMT prescription that is under their health plan formulary. Majority of the patients (92.9%) were prescribed 30 days’ supply of DMTs, 6.3% were on 90 days’ supply and only 0.8% were on 60 days’ supply of DMTs. More than half of the patients (55.7%) were diagnosed with mental health problems in addition to their RRMS as a primary diagnosis. On average, patients were continuously enrolled for 5.36 ± 2.40 years and submitting around 446 claims during this period.  CONCLUSIONS: The majority of the patients was females and was between 41 to 64 years of age. And majority of the patients received 30 days’ supply of DMTs.